A PLS approach using time as the dependent variable

A PLS approach using time as the dependent variable http://www.selleckchem.com/products/MLN8237.html and the item scores as the independent variables essentially uses time and clinical decline as the ‘gold standard’, combining the best attributes of a principal components approach with the best attributes of an exhaustive search or OLS approach based on time. Using the MSDR to identify the best composite score results in selection of an outcome measure that tracks most sensitively with progression because the MSDR measures the external responsiveness to time. This approach is based on the placebo group decline and assumes a constant percentage reduction in the active group. So this approach is more appropriate for a disease-modifying treatment that may be expected to impact all clinical disease progression similarly than for a symptomatic treatment that is likely to have a larger effect on some symptoms than on others.

Composite cognitive scales that combine items from neuropsychological tests offer improved measurement of decline in a pre-MCI population. In an MCI stage, a composite that considers cognitive, functional, and global items is likely to give the best chance for optimal measurement of decline, reflects a global approach to the disease and would be particularly useful for proof-of-concept studies. A composite that is restricted to cognitive items in an MCI stage would offer improvement over standard clinical outcomes and would offer the simplicity of measuring a single domain of progression. Either of these two approaches could be used in parallel with an appropriate biomarker outcome such as volumetric MRI for a treatment that is expected to slow disease progression.

The combination of enrichment of the study population and optimization of sensitivity to decline Carfilzomib by using a weighted composite score gives us the best chance to improve the efficiency of a clinical trial in a pre-MCI or MCI population. This improved efficiency allows us to perform shorter, smaller studies than would otherwise be required. In addition, this this research approach could give us more confidence in a positive or negative result or allow us to get a more accurate estimate of a treatment effect in an inconclusive proof-of-concept study. Abbreviations AD: Alzheimer’s disease; ADAS-cog: Alzheimer’s Disease Assessment Scale cognitive subscale; ADCS: Alzheimer’s Disease Cooperative Study; CDR-sb: Clinical Dementia Rating: sum of boxes; CSF: cerebral spinal fluid; FDG-PET: 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography; MCI: mild cognitive impairment; MMSE: mini-mental status examination; MRI: magnetic resonance imaging; MSDR: mean to standard deviation ratio; OLS: ordinary least squares; PET: positron emission tomography; PLS: partial least squares.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>